1. SUMO Rules: Regulatory Concepts and Their Implication in Neurologic Functions
    Mathias Droescher et al, 2013, NeuroMolecular Medicine CrossRef
  2. The UBC9/SUMO pathway affects E-cadherin cleavage in HPV-positive head and neck cancer
    Maria Elisa Sabatini et al, 2022, Frontiers in Molecular Biosciences CrossRef
  3. The post-translational modification, SUMOylation, and cancer (Review)
    Zhi-Jian Han et al, 2018, International Journal of Oncology CrossRef
  4. Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis
    Pei-Fang Hung et al, 2019, Journal of Experimental & Clinical Cancer Research CrossRef
  5. Inhibition of the Ubc9 E2 SUMO-conjugating enzyme–CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain
    Liberty François-Moutal et al, 2018, Pain CrossRef
  6. The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer
    Nicole E. Pellegrino et al, 2022, International Journal of Molecular Sciences CrossRef
  7. A novel cell-permeable peptide prevents protein SUMOylation and supports the mislocalization and aggregation of TDP-43
    R. Marino et al, 2023, Neurobiology of Disease CrossRef
  8. The RNA helicase A in malignant transformation
    Marco Fidaleo et al, 2016, Oncotarget CrossRef
  9. Ubiquitin-Conjugating Enzymes in Cancer
    Quyen Thu Bui et al, 2021, Cells CrossRef
  10. UBE2I promotes metastasis and correlates with poor prognosis in hepatocellular carcinoma
    Hao Yang et al, 2020, Cancer Cell International CrossRef
  11. Dissecting multiple roles of SUMOylation in prostate cancer
    Yishu Wang et al, 2021, Cancer Letters CrossRef
  12. SP1 transcriptionally regulates UBE2N expression to promote lung adenocarcinoma progression
    Jianjun Li et al, 2023, Molecular Biomedicine CrossRef
  13. The emerging roles of SUMOylation in pulmonary diseases
    Xuyang Zheng et al, 2023, Molecular Medicine CrossRef
  14. Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases
    Dexiang Hua et al, 2022, European Journal of Medicinal Chemistry CrossRef
  15. Identification of UBE2I as a Novel Biomarker in ccRCC Based on a Large-Scale CRISPR-Cas9 Screening Database and Immunohistochemistry
    Feng Li et al, 2022, Frontiers in Molecular Biosciences CrossRef
  16. Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma
    Toshihide Nishimura et al, 2020, Scientific Reports CrossRef
  17. Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer
    Xiaoke Liu et al, 2015, Journal of Hematology & Oncology CrossRef
  18. Involvement of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 in Ubc9-mediated resistance to chemotherapy agents
    Yang Chen et al, 2017, International Journal of Oncology CrossRef
  19. SUMOylation in Glioblastoma: A Novel Therapeutic Target
    Brandon M. Fox et al, 2019, International Journal of Molecular Sciences CrossRef
  20. The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis
    null Dehnavi et al, 2019, Journal of Clinical Medicine CrossRef
  21. SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer
    Karolin Eifler et al, 2015, Trends in Biochemical Sciences CrossRef
  22. PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation
    Luyao Wei et al, 2022, Oncogene CrossRef
  23. SUMO pathway components as possible cancer biomarkers
    Domenico Mattoscio et al, 2015, Future Oncology CrossRef
  24. Characterization of amino acid residues within the N-terminal region of Ubc9 that play a role in Ubc9 nuclear localization
    Palak Sekhri et al, 2015, Biochemical and Biophysical Research Communications CrossRef
  25. SUMOylation of KLF4 acts as a switch in transcriptional programs that control VSMC proliferation
    Chan-juan Nie et al, 2016, Experimental Cell Research CrossRef
  26. SUMO proteomics to decipher the SUMO‐modified proteome regulated by various diseases
    Wei Yang et al, 2015, PROTEOMICS CrossRef
  27. Delineating the HMGB1 and HMGB2 interactome in prostate and ovary epithelial cells and its relationship with cancer
    Aida Barreiro-Alonso et al, 2018, Oncotarget CrossRef
  28. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs
    Guofang Hou et al, 2021, Nucleic Acids Research CrossRef
  29. Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds
    Yanfang Yang et al, 2018, Molecular Pharmacology CrossRef